CytomX Therapeutics (NASDAQ:CTMX) Upgraded to “Hold” at ValuEngine

ValuEngine upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a sell rating to a hold rating in a report published on Thursday, ValuEngine reports.

A number of other research firms have also weighed in on CTMX. Zacks Investment Research upgraded shares of CytomX Therapeutics from a hold rating to a strong-buy rating and set a $14.00 price objective for the company in a research note on Wednesday, July 17th. Nomura reduced their price objective on shares of CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. BidaskClub lowered shares of CytomX Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 24th. Cantor Fitzgerald reiterated an overweight rating and issued a $23.00 price objective (up from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Finally, Mizuho reiterated a buy rating and issued a $16.00 price objective on shares of CytomX Therapeutics in a research note on Monday, July 29th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $20.22.

CytomX Therapeutics stock traded down $0.19 during mid-day trading on Thursday, reaching $10.06. The company’s stock had a trading volume of 180,602 shares, compared to its average volume of 305,101. CytomX Therapeutics has a 12-month low of $8.94 and a 12-month high of $25.79. The firm has a market cap of $467.16 million, a P/E ratio of -4.96 and a beta of 0.64. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.22. The stock has a fifty day moving average of $11.01.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.22. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. The business had revenue of $29.49 million during the quarter, compared to analyst estimates of $13.59 million. Equities analysts expect that CytomX Therapeutics will post -2.1 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. Legal & General Group Plc boosted its holdings in CytomX Therapeutics by 18.6% in the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 1,306 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in CytomX Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,700 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,600 shares during the period. Bank of America Corp DE boosted its holdings in CytomX Therapeutics by 6.5% in the 4th quarter. Bank of America Corp DE now owns 55,574 shares of the biotechnology company’s stock valued at $839,000 after purchasing an additional 3,416 shares during the period. Strs Ohio boosted its holdings in CytomX Therapeutics by 7.5% in the 2nd quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 4,200 shares during the period. Finally, Pictet Asset Management Ltd. boosted its holdings in CytomX Therapeutics by 0.9% in the 1st quarter. Pictet Asset Management Ltd. now owns 611,356 shares of the biotechnology company’s stock valued at $6,572,000 after purchasing an additional 5,670 shares during the period. 81.81% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: What is an Initial Public Offering (IPO)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.